MA53921A - Inhibiteurs de protéine tyrosine phosphatase - Google Patents
Inhibiteurs de protéine tyrosine phosphataseInfo
- Publication number
- MA53921A MA53921A MA053921A MA53921A MA53921A MA 53921 A MA53921 A MA 53921A MA 053921 A MA053921 A MA 053921A MA 53921 A MA53921 A MA 53921A MA 53921 A MA53921 A MA 53921A
- Authority
- MA
- Morocco
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- phosphatase inhibitors
- inhibitors
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746952P | 2018-10-17 | 2018-10-17 | |
US201962916119P | 2019-10-16 | 2019-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53921A true MA53921A (fr) | 2022-01-26 |
Family
ID=68536896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053921A MA53921A (fr) | 2018-10-17 | 2019-10-17 | Inhibiteurs de protéine tyrosine phosphatase |
Country Status (27)
Country | Link |
---|---|
US (1) | US20210380582A1 (fr) |
EP (1) | EP3867238B1 (fr) |
JP (1) | JP7449282B2 (fr) |
KR (1) | KR102649419B1 (fr) |
CN (1) | CN114341124A (fr) |
AU (1) | AU2019359885B2 (fr) |
BR (1) | BR112021005733A2 (fr) |
CA (1) | CA3116561C (fr) |
CL (1) | CL2021000972A1 (fr) |
CO (1) | CO2021004966A2 (fr) |
CR (1) | CR20210189A (fr) |
CU (1) | CU20210029A7 (fr) |
CY (1) | CY1126122T1 (fr) |
DO (1) | DOP2021000070A (fr) |
EC (1) | ECSP21027049A (fr) |
ES (1) | ES2947464T3 (fr) |
HU (1) | HUE062404T2 (fr) |
IL (1) | IL282179A (fr) |
MA (1) | MA53921A (fr) |
MX (1) | MX2021004410A (fr) |
NI (1) | NI202100027A (fr) |
PE (1) | PE20211465A1 (fr) |
PH (1) | PH12021550674A1 (fr) |
PL (1) | PL3867238T3 (fr) |
SG (1) | SG11202102985YA (fr) |
WO (1) | WO2020081848A1 (fr) |
ZA (1) | ZA202101960B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
EP3768668A1 (fr) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Inhibiteurs de la phosphatase shp2 et leurs procédés d'utilisation |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
CA3135555C (fr) | 2019-04-02 | 2023-09-19 | Array Biopharma Inc. | Inhibiteurs de proteine tyrosine phosphatase |
CA3154862A1 (fr) | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2, procedes de production et d'utilisation associes |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
EP4208261A1 (fr) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2 |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶-1,6(2h,7h)-二酮 |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技(上海)有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
CN115960109A (zh) * | 2021-05-31 | 2023-04-14 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
AU2022309195A1 (en) | 2021-07-09 | 2024-01-25 | Kanaph Therapeutics Inc. | Shp2 inhibitor and use thereof |
CA3224341A1 (fr) | 2021-09-01 | 2023-03-09 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023133225A1 (fr) * | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Composés et procédés de modulation d'épissage |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
CN114621186A (zh) * | 2022-05-12 | 2022-06-14 | 上海维申医药有限公司 | 作为ras信号通路调控剂的杂环化合物 |
WO2023230205A1 (fr) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Inhibiteurs de mek et leurs utilisations |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
WO2007029847A1 (fr) * | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Dérivé de pyridone substitué aromatique bicylique |
WO2011032050A2 (fr) * | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Inhibiteurs de gyrase |
JP5894980B2 (ja) * | 2010-05-24 | 2016-03-30 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
WO2016203405A1 (fr) | 2015-06-19 | 2016-12-22 | Novartis Ag | Composés et compositions pour inhiber l'activité de shp2 |
CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
EP3310779B1 (fr) | 2015-06-19 | 2019-05-08 | Novartis AG | Composés et compositions pour l'inhibition de l'activité de shp2 |
EP4108659A1 (fr) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs shp2 |
EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CA3074690A1 (fr) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Compositions d'inhibiteur de la shp2 et methodes de traitement du cancer |
-
2019
- 2019-10-17 PE PE2021000527A patent/PE20211465A1/es unknown
- 2019-10-17 MX MX2021004410A patent/MX2021004410A/es unknown
- 2019-10-17 US US17/285,997 patent/US20210380582A1/en active Pending
- 2019-10-17 CA CA3116561A patent/CA3116561C/fr active Active
- 2019-10-17 CN CN201980068343.2A patent/CN114341124A/zh active Pending
- 2019-10-17 EP EP19801996.0A patent/EP3867238B1/fr active Active
- 2019-10-17 MA MA053921A patent/MA53921A/fr unknown
- 2019-10-17 WO PCT/US2019/056786 patent/WO2020081848A1/fr active Application Filing
- 2019-10-17 HU HUE19801996A patent/HUE062404T2/hu unknown
- 2019-10-17 AU AU2019359885A patent/AU2019359885B2/en active Active
- 2019-10-17 SG SG11202102985YA patent/SG11202102985YA/en unknown
- 2019-10-17 JP JP2021520556A patent/JP7449282B2/ja active Active
- 2019-10-17 CR CR20210189A patent/CR20210189A/es unknown
- 2019-10-17 KR KR1020217014574A patent/KR102649419B1/ko active IP Right Grant
- 2019-10-17 PL PL19801996.0T patent/PL3867238T3/pl unknown
- 2019-10-17 CU CU2021000029A patent/CU20210029A7/es unknown
- 2019-10-17 BR BR112021005733-1A patent/BR112021005733A2/pt unknown
- 2019-10-17 ES ES19801996T patent/ES2947464T3/es active Active
-
2021
- 2021-03-24 ZA ZA2021/01960A patent/ZA202101960B/en unknown
- 2021-03-25 PH PH12021550674A patent/PH12021550674A1/en unknown
- 2021-04-08 IL IL282179A patent/IL282179A/en unknown
- 2021-04-16 CL CL2021000972A patent/CL2021000972A1/es unknown
- 2021-04-16 EC ECSENADI202127049A patent/ECSP21027049A/es unknown
- 2021-04-16 DO DO2021000070A patent/DOP2021000070A/es unknown
- 2021-04-16 NI NI202100027A patent/NI202100027A/es unknown
- 2021-04-19 CO CONC2021/0004966A patent/CO2021004966A2/es unknown
-
2023
- 2023-08-01 CY CY20231100379T patent/CY1126122T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021000972A1 (es) | 2021-10-15 |
ZA202101960B (en) | 2023-11-29 |
PE20211465A1 (es) | 2021-08-05 |
CR20210189A (es) | 2021-09-14 |
AU2019359885A1 (en) | 2021-04-15 |
CY1126122T1 (el) | 2023-11-15 |
AU2019359885B2 (en) | 2024-01-18 |
HUE062404T2 (hu) | 2023-10-28 |
BR112021005733A2 (pt) | 2021-07-27 |
CU20210029A7 (es) | 2021-11-04 |
IL282179A (en) | 2021-05-31 |
KR20210076098A (ko) | 2021-06-23 |
CN114341124A (zh) | 2022-04-12 |
CA3116561C (fr) | 2023-09-12 |
EP3867238A1 (fr) | 2021-08-25 |
EP3867238B1 (fr) | 2023-06-07 |
PL3867238T3 (pl) | 2023-09-11 |
DOP2021000070A (es) | 2021-05-16 |
JP7449282B2 (ja) | 2024-03-13 |
MX2021004410A (es) | 2021-07-06 |
SG11202102985YA (en) | 2021-05-28 |
EP3867238C0 (fr) | 2023-06-07 |
WO2020081848A1 (fr) | 2020-04-23 |
NI202100027A (es) | 2021-08-24 |
ECSP21027049A (es) | 2021-05-31 |
US20210380582A1 (en) | 2021-12-09 |
JP2022504936A (ja) | 2022-01-13 |
PH12021550674A1 (en) | 2021-12-13 |
ES2947464T3 (es) | 2023-08-09 |
CO2021004966A2 (es) | 2021-04-30 |
CA3116561A1 (fr) | 2020-04-23 |
KR102649419B1 (ko) | 2024-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
MA55511A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
MA54543A (fr) | Inhibiteurs de kif18a | |
MA54550A (fr) | Inhibiteurs de kif18a | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA51616A (fr) | Inhibiteurs d'adn-pk | |
MA52812A (fr) | Inhibiteurs de sarm1 | |
MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
DK3810602T3 (da) | Forbindelser | |
MA53287A (fr) | Inhibiteurs de prmt5 | |
MA52635A (fr) | Inhibiteurs de magl | |
CL2021000426A1 (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2. | |
MA55909A (fr) | Inhibiteurs de cdk | |
MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
MA50675A (fr) | Inhibiteurs de la creb binding protein (cbp) | |
MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
DK3591122T3 (da) | Hurtigskifter | |
MA52809A (fr) | Inhibiteurs de sarm1 | |
MA52813A (fr) | Inhibiteurs de sarm1 | |
DK3810633T3 (da) | Forbindelser | |
DK3775477T3 (da) | Brøndområdeisoleringssystem | |
DK3528475T3 (da) | Målesystem | |
DK3793895T3 (da) | Udstødningssystem | |
DK3972389T3 (da) | Belysningssystem | |
DK3781726T3 (da) | Fotovoltaisk-elektrokemisk (pv-ec) system |